Kevin Hershberger Joins Lumicell as Chief Financial Officer
Hershberger brings over 25 years of global financial management experience from a variety of life science products and manufacturing companies
Wellesley, Mass., Sept. 18, 2018— Lumicell, Inc., an innovation leader in molecular imaging, within healthcare focused in cancer, perfusion, wound care and infection, today announced the addition of Kevin Hershberger as Chief Financial Officer (CFO).
To Lumicell, Hershberger brings over 25 years of global financial management experience in a variety of life science products and manufacturing companies with an extensive range of expertise and leadership responsibilities. In this highly-visible leadership role, Hershberger will be responsible for laying the foundation for the financial success of Lumicell and preparing the overall business for commercialization.
“In addition to his broad financial acumen and decades-long career in manufacturing and life sciences companies, Kevin has an excellent reputation for building strong teams and structuring successful companies,” said Kelly Londy, CEO, Lumicell. “At Lumicell, we know that great companies start with great technology – but great technology doesn’t come to fruition without great people implementing a strong strategy. Kevin will join our leadership team and help pave the way for the future success of our organization.”
“It’s an exciting time to be joining the team at Lumicell,” said Hershberger. “The company is on the precipice of significant innovations and making far-reaching strides in bringing its drug and device therapy to the market where it can help physicians and patients. But what I’m most excited about is Lumicell’s mission. Cancer, infection, wound care—battling these tough diseases is personal. And I look forward to supporting this mission, helping raise the profile of Lumicell’s technology, and improving people’s lives.”
Hershberger most recently served as CFO of ReWalk Robotics (RWLK) where he built out the company’s finance function and helped bring together a partnership with Harvard University’s Wyss Institute encompassing a broad licensing and collaboration agreement to develop a Softsuit Exoskeleton. Prior to ReWalk, he held leadership roles with NxStage Medical as the Vice President of Finance, Controller, and Chief Accounting Officer during a period of significant growth and expansion. Mr. Hershberger also spent nearly ten years in positions of increasing responsibilities at Boston Scientific.
About Lumicell, Inc.
Lumicell is a technology leader in the field of image-guided cancer surgery. The company is developing a novel system that enables real-time detection of tumor tissue in patients so that no cancer cells are left behind during surgery. The company’s LUM System has unprecedented ability to see and remove cancer cells remaining in the surgical cavity – beyond the margin of the specimen – and has the potential to significantly improve surgical outcomes and reduce healthcare costs by eliminating the need for repeat surgeries. Lumicell is investigating the LUM System in patients undergoing surgery for breast cancer, prostate cancer, colorectal, esophageal and pancreatic cancers. Additional future indications are planned to include surgeries for lung, ovarian, and brain cancers. For more information, please visit www.lumicell.com.
Media contact: Ali Buckneberg
Phone number: 612-334-5960